Balchem Corporation(BCPC) Stock Research - Grey Stern Research

Balchem Corporation (BCPC) Stock Analysis

$178.28 (1.27%)

BCPC Financial Performance


Use the table below to view Balchem Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $176.04 -
52 Week Low $110.74 -
52 Week High $186.03 -
Market Cap $5.7 Billion 3/10
Gross Margin 35% 1/10
Profit Margin 14% 1/10
EBITDA margin 25% 2/10
Q2 - 2024 Revenue $234.1 Million 9/10
Q2 - 2024 Earnings $32.1 Million 5/10
Q2 - 2024 Free Cash Flow $38.1 Million 5/10
Trailing 4 Quarters Revenue $932.4 Million 9/10
Trailing 4 Quarters Earnings $116.8 Million 7/10
Quarterly Earnings Growth 7% 6/10
Annual Earnings Growth 19% 5/10
Quarterly Revenue Growth 1% 5/10
Annual Revenue Growth 0% 6/10
Cash On Hand $63.7 Million 8/10
Short Term Debt $3.8 Million 8/10
Long Term Debt $266.6 Million 8/10

Balchem Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Balchem Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 48.91 1/10
PS 6.13 1/10
PB 5.13 1/10
PC 89.61 2/10
Liabilities to Equity 0.42 9/10
ROA 0.07 4/10
ROE 0.10 5/10
Current Ratio 3.40 1/10
Quick Ratio 0.14 7/10
Long Term Debt to Equity 0.24 8/10
Debt to Equity 0.26 9/10
Burn Rate -3.12 7/10
Cash to Cap 0.01 9/10
CCR 1.19 5/10
EV to EBITDA 101.54 1/10
EV to Revenue 6.36 1/10

Company Details

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.

CEO: Mr. Theodore Harris

Website: https://www.balchem.com

Address: 52 Sunrise Park Rd New Hampton, NEW YORK

Exchange: NASDAQ Global Select

Industry: Specialty Chemicals

Balchem Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Balchem Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Axalta Coating Systems Ltd. AXTA $8.1 Billion
Ashland Global Holdings Inc. ASH $4.3 Billion
Cabot Corporation CBT $6.1 Billion
Sensient Technologies Corporation SXT $3.4 Billion
H.B. Fuller Company FUL $4.6 Billion
Minerals Technologies Inc. MTX $2.4 Billion
Innospec Inc. IOSP $2.8 Billion
Quaker Chemical Corporation KWR $3.1 Billion
Oil-Dri Corporation of America ODC $463.6 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
BCPC Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 234.1 Million $32.1 Million
Q1 2024 $ 239.7 Million $29.0 Million
Q4 2023 $ 228.7 Million $26.6 Million
Q3 2023 $ 229.9 Million $29.1 Million
Q2 2023 $ 231.3 Million $30.1 Million
Q1 2023 $ 232.5 Million $22.7 Million
Q4 2022 $ 232.5 Million $21.4 Million
Q3 2022 $ 244.3 Million $25.2 Million

View All

BCPC Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $63.7 Million $1.6 Billion $285.9 Million $1.1 Billion
Q1 2024 $60.3 Million $1.6 Billion $321.5 Million $1.1 Billion
Q4 2023 $64.4 Million $1.6 Billion $330.3 Million $1.1 Billion
Q3 2023 $77.0 Million $1.6 Billion $34.5 Million $1.0 Billion
Q2 2023 $66.9 Million $1.6 Billion $424.8 Million $1.0 Billion
Q1 2023 $60.2 Million $1.6 Billion $431.6 Million $973.4 Million
Q4 2022 $66.6 Million $1.6 Billion $440.6 Million $938.3 Million
Q3 2022 $56.5 Million $1.6 Billion $29.0 Million $895.9 Million

View All

BCPC Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $38.1 Million -$6.9 Million $3.4 Million
Q1 2024 $26.5 Million -$6.9 Million -$4.1 Million
Q4 2023 $55.8 Million -$11.6 Million -$12.5 Million
Q3 2023 $61,000 $0 $61,000
Q2 2023 $26.8 Million -$8.2 Million $6.7 Million
Q1 2023 $25.1 Million -$9.7 Million -$6.4 Million
Q4 2022 $27.2 Million -$14.5 Million $10.1 Million
Q3 2022 $26.6 Million -$15.0 Million -$19.7 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions